CN105816952A - Novel electret microneedle transdermal drug delivery system - Google Patents
Novel electret microneedle transdermal drug delivery system Download PDFInfo
- Publication number
- CN105816952A CN105816952A CN201610005552.0A CN201610005552A CN105816952A CN 105816952 A CN105816952 A CN 105816952A CN 201610005552 A CN201610005552 A CN 201610005552A CN 105816952 A CN105816952 A CN 105816952A
- Authority
- CN
- China
- Prior art keywords
- layer
- electret
- micropin
- microneedle
- sensitive adhesive
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0092—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin using ultrasonic, sonic or infrasonic vibrations, e.g. phonophoresis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
- A61M2037/0023—Drug applicators using microneedles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
- A61M2037/003—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles having a lumen
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Medical Informatics (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention relates to the technical field of medicines, in particular to a novel electret microneedle transdermal drug delivery system. The system comprises an isolation layer and a drug-containing pressure-sensitive adhesive layer arranged on the inner side of the isolation layer, wherein an electret layer made from an electret material is arranged on the outer side of the isolation layer; a controlled-release membrane layer is arranged on the inner side of the drug-containing pressure-sensitive adhesive layer; the electret layer, the isolation layer, the drug-containing pressure-sensitive adhesive layer and the controlled-release membrane layer are arranged in sequence from outside to inside to form a reservoir type patch; a microneedle array layer is arranged on the inner side of the reservoir type patch and comprises a microneedle array formed by a plurality of microneedles; each microneedle is 20-50 microns in diameter; and the spacing between every two adjacent microneedles is 1-1.5mm. According to the system, a drug can conveniently penetrate the skin by optimizing microneedle structure and arrangement; and when the system is used, the microneedles act on the skin firstly, the drug quickly penetrates the skin through the needle holes of the microneedles, and the electret layer accelerates drug penetration to achieve a treatment effect.
Description
Technical field
The present invention relates to pharmaceutical technology field, be specifically related to a kind of drug-supplying system.
Background technology
Transdermal drug delivery system refers to be administered at skin surface, makes medicine with constant rate of speed or enter body close to constant rate of speed by skin and circulate, produces whole body or the novel form of local therapeutic effects.Its advantage is embodied in: drug absorption is not affected by factors such as PH, food, transhipment times in digestive tract；Avoid liver by effect；Overcome the untoward reaction caused because the too fast generation haemoconcentration of absorption is too high；Sustainable control injection speed, flexible administration etc..
But existing transdermal drug delivery system is commonly present defects such as drug molecule amount and polarity restrictions, there is also drug delivery dosage be not easily controlled, the problem such as poor air permeability.
The most existing transdermal drug delivery system there is also the shortcomings such as seepage velocity is slow, drug utilization is the most abundant.
Summary of the invention
It is an object of the invention to, it is provided that a kind of microneedle cutaneous system of novel electret, solve above technical problem.
Technical problem solved by the invention can realize by the following technical solutions:
The microneedle cutaneous system of novel electret, including a sealing coat, it is arranged on the pastille pressure-sensitive adhesive layer inside described sealing coat, it is characterised in that, the outside of described sealing coat is provided with the electret layer that an employing electret is made, and the inner side of described pastille pressure-sensitive adhesive layer is provided with a release-controlled film layer；
It is placed with described electret layer, described sealing coat, described pastille pressure-sensitive adhesive layer and described release-controlled film layer successively by outer and interior, forms a reservoir devices patch；
Being provided with a microneedle array layer inside described reservoir devices patch, described microneedle array layer includes the microneedle array that a plurality of micropin is formed；
A diameter of 20 microns～50 microns of described micropin, the spacing of adjacent described micropin is 1mm～1.5mm.
The present invention weakens skin barrier, makes keratodermatitis structural change, accelerates drug osmotic.The present invention is by optimizing the structure of micropin in arrangement, it is simple to infiltrate through skin, and when the present invention uses, first with micropin effect skin, medicine enters skin by the pin hole rapid osmotic of micropin, and electret layer accelerates the infiltration of medicine, reaches therapeutic effect.The experiment proved that, above-mentioned micropin size is with under arrangement state, and administering effect is optimal.
The micropin that described microneedle array is provided with includes degradable first micropin, nondegradable second micropin, and described first micropin is adjacent with described second micropin to be arranged alternately in described microneedle array layer；
Medicine is included in described first micropin.
The present invention uses the structure of single material by optimizing tradition microneedle array layer, by degradable first micropin and the combination of the second micropin, it is achieved that while the medicine in pastille pressure-sensitive adhesive layer is carried by the first micropin, it is achieved that the effect of administration.
Medicine in described first micropin is consistent with the medicine in described pastille pressure-sensitive adhesive layer.
Prevent the inconsistent property of medicine conflict caused of medicine.
A length of 500 microns～1800 microns of described micropin.
It is easy to ensure administering effect.
Being provided with a micromotor outside described electret layer, described micromotor connects an eccentric by drive disk assembly, and described eccentric props up described electret layer.
While being suitable for domestic, improve administering effect.
Posting a ultrasound wave genetic horizon outside described electret layer, ultrasound wave genetic horizon connects a ultrasonic output circuit；
Described ultrasound wave genetic horizon includes the piezoelectric ceramic piece consistent with micropin number, and the arrangement of described piezoelectric ceramic piece is consistent with the arrangement of described micropin, and described piezoelectric ceramic piece is on same straight line with the central axis of described micropin.
The ul-trasonic irradiation that ultrasound wave genetic horizon sends, in described pastille pressure-sensitive adhesive layer and electret layer, can improve pharmaceutically active, improve water activity promotion drug absorption in skin.
Viscosifier, transdermal enhancer and the antioxidant being dispersed in described substrate it is additionally provided with in described pastille pressure-sensitive adhesive layer.Preferably to work in coordination with rush together to ooze.
A metal electrode layer is also posted outside described electret layer, described metal electrode layer connects the polarity reversing device of an adjustment metal electrode layer polarity of electrode, described polarity reversing device connects a microprocessor system, and described microprocessor system connects a clock module.
The present invention uses electret as the physical regulating factor, can provide electrostatic field and micro-electric current as ion-drive source to skin, regulates and controls the electret state of skin, electricity structure and strengthens ionic drug Transdermal absorption.The control to electrostatic field in electret Yu micro-electric current is realized by metal electrode layer.
Permanent magnet powder granule is also distributed in described pastille pressure-sensitive adhesive layer.Permanent magnet powder granule can use Ru-Fe-Mn permanent magnet powder granule.Molecular activity can be promoted by magnetic field, the activity of hydrone in human body can be promoted especially.
Described pastille pressure-sensitive adhesive layer includes containing 5-fluorouracil, somatomedin, the substrate of GLP-1 or DPP-4 any one medicine of inhibitor.
Or, described pastille pressure-sensitive adhesive layer includes the substrate containing this medicine of 5-fluorouracil, and described substrate is possibly together with somatomedin, any one medicine of GLP-1 or DPP-4 inhibitor.
As a kind of preferred version, described pastille pressure-sensitive adhesive layer includes containing 5-fluorouracil, somatomedin, the substrate of GLP-1 medicine.
Being additionally provided with stearyl alcohol glycyrrhetin acid esters in described pastille pressure-sensitive adhesive layer, stearyl alcohol glycyrrhetin acid esters and GLP-1 mass ratio are 1:10.Stearyl alcohol glycyrrhetin acid esters moisturizing and inflammation-diminishing function are strong, also have antibacterial, antiinflammatory, antioxidation, defying age, whitening skin lightening, effect of speckle dispelling.
Described stearyl alcohol glycyrrhetin acid esters is positioned at outside described substrate.
Described stearyl alcohol glycyrrhetin acid esters outsourcing has a liposome, is provided with the isopropyl myristate of 20%～50% and the stearyl alcohol glycyrrhetin acid esters of 40%～60% in liposome.
Realize dispelling the effect of scar skin care.
The medicine that described pastille pressure-sensitive adhesive layer contains also includes that water soluble dietary fiber, water soluble dietary fiber are 3:7 with the mass ratio of GLP-1.
The present invention is easy to treat diabetes, does not results in gastrointestinal and does not tolerates, and does not interferes with the absorption of other nutrients.
The medicine that described pastille pressure-sensitive adhesive layer contains also includes water soluble dietary fiber, vitamin b1, and water soluble dietary fiber, vitamin b1 and GLP-1 three's mass ratio are 2:2:6.
The present invention is easy to treat diabetes, does not results in gastrointestinal and does not tolerates, and does not interferes with the absorption of other nutrients.In diabetics body, vitamin b1 level is significantly lower than normal person simultaneously, and therefore diabetics suitable vitimin supplement b1 is useful.
Described medicine is provided with a surrounding layer being made up of liposome.Liposome can be monounsaturated fatty acid.The opposing to insulin can be reduced, improve administering effect.
Described substrate uses water-free substrate, and described substrate includes non-polar polymer and plasticizer.Moisture free substrate can improve the stability of medicine, and patch compliance is good, and adhesiveness is suitable.
Viscosifier, transdermal enhancer and the antioxidant being dispersed in described substrate it is additionally provided with in described pastille pressure-sensitive adhesive layer.Preferably to work in coordination with rush together to ooze.
Described first micropin includes double-decker, respectively internal layer and outer layer, and described outer layer is to be made up of biodegradable polymer, and described internal layer includes at least one in GLP-1, DPP-4 inhibitor both medicines.Described biodegradable polymer is PLGA.
Described biodegradable polymer is
Wherein ,-PEA-is-PEUR isN is the scope of 50 to 150, and m is the scope of 0.1 to 0.9；P is the scope of 0.9 to 0.1.R1 is selected from C6Alkylidene or C7Alkenylene；R2 is hydrogen or C6Alkyl；R3 is selected from hydrogen, (C2-C6) alkyl, (C2-C6) thiazolinyl and (C2-C6) alkynyl；With R4 selected from (C2-C6) alkylidene, (C2-C6) alkenylene or alkoxyl.
While facilitating implementation degraded, it is achieved the treatment to diabetes.
Permanent magnet powder granule is also distributed in described pastille pressure-sensitive adhesive layer.Permanent magnet powder granule can use Ru-Fe-Mn permanent magnet powder granule.Molecular activity can be promoted by magnetic field, the activity of hydrone in human body can be promoted especially.
Tourmaline powder particle is also distributed in described pastille pressure-sensitive adhesive layer.
Accompanying drawing explanation
Fig. 1 is the part-structure schematic diagram of the present invention.
Detailed description of the invention
For the technological means making the present invention realize, creation characteristic, reach purpose and be easy to understand with effect, the present invention is expanded on further below in conjunction with being specifically illustrating.
With reference to Fig. 1, the microneedle cutaneous system of novel electret, including a sealing coat 23, is arranged on the pastille pressure-sensitive adhesive layer 22 inside sealing coat 23, the outside of sealing coat 23 is provided with the electret layer 24 that an employing electret is made, and the inner side of pastille pressure-sensitive adhesive layer 22 is provided with a release-controlled film layer 21；It is placed with electret layer 24, sealing coat 23, pastille pressure-sensitive adhesive layer 22 and release-controlled film layer 21 successively by outer and interior, forms a reservoir devices patch；Being provided with a microneedle array layer inside reservoir devices patch, microneedle array layer includes the microneedle array that a plurality of micropin 11 is formed；A diameter of 20 microns～50 microns of micropin 11, the spacing of adjacent micropin 11 is 1mm～1.5mm.The present invention weakens skin barrier, makes keratodermatitis structural change, accelerates drug osmotic.The present invention is by optimizing the structure of micropin 11 in arrangement, it is simple to infiltrating through skin, when the present invention uses, first act on skin with micropin 11, medicine enters skin by the pin hole rapid osmotic of micropin 11, and electret layer 24 accelerates the infiltration of medicine, reaches therapeutic effect.The experiment proved that, above-mentioned micropin 11 size is with under arrangement state, and administering effect is optimal.
The micropin 11 that micropin 11 array is provided with includes degradable first micropin, nondegradable second micropin, the first micropin and the second micropin is adjacent is arranged alternately in microneedle array layer；Medicine is included in first micropin.The present invention uses the structure of single material by optimizing tradition microneedle array layer, by degradable first micropin and the combination of the second micropin, it is achieved that while the medicine in pastille pressure-sensitive adhesive layer 22 is carried by the first micropin, it is achieved that the effect of administration.
Medicine in first micropin is consistent with the medicine in pastille pressure-sensitive adhesive layer 22.Prevent the inconsistent property of medicine conflict caused of medicine.
A length of 500 microns～1800 microns of micropin.It is easy to ensure administering effect.
Being provided with a micromotor outside electret layer, micromotor connects an eccentric by drive disk assembly, and eccentric props up electret layer.While being suitable for domestic, improve administering effect.
Posting a ultrasound wave genetic horizon outside electret layer 24, ultrasound wave genetic horizon connects a ultrasonic output circuit；Ultrasound wave genetic horizon includes the piezoelectric ceramic piece consistent with micropin number, and the arrangement of piezoelectric ceramic piece is consistent with the arrangement of micropin, and piezoelectric ceramic piece is on same straight line with the central axis of micropin.The ul-trasonic irradiation that ultrasound wave genetic horizon sends, in pastille pressure-sensitive adhesive layer 22 and electret layer 24, can improve pharmaceutically active, improve water activity promotion drug absorption in skin.Viscosifier, transdermal enhancer and the antioxidant being dispersed in substrate it is additionally provided with in pastille pressure-sensitive adhesive layer 22.Preferably to work in coordination with rush together to ooze.
Also posting a metal electrode layer outside electret layer 24, metal electrode layer connects the polarity reversing device of an adjustment metal electrode layer polarity of electrode, and polarity reversing device connects a microprocessor system, and microprocessor system connects a clock module.The present invention uses electret as the physical regulating factor, can provide electrostatic field and micro-electric current as ion-drive source to skin, regulates and controls the electret state of skin, electricity structure and strengthens ionic drug Transdermal absorption.The control to electrostatic field in electret Yu micro-electric current is realized by metal electrode layer.
Permanent magnet powder granule is also distributed in pastille pressure-sensitive adhesive layer 22.Permanent magnet powder granule can use Ru-Fe-Mn permanent magnet powder granule.Molecular activity can be promoted by magnetic field, the activity of hydrone in human body can be promoted especially.Pastille pressure-sensitive adhesive layer 22 includes containing 5-fluorouracil, somatomedin, the substrate of GLP-1 or DPP-4 any one medicine of inhibitor.Pastille pressure-sensitive adhesive layer 22 includes containing 5-fluorouracil, somatomedin, the substrate of GLP-1 or DPP-4 at least one medicine of inhibitor.To improve treatment hypertrophic cicatrix or the curative effect of diabetes or to provide a kind of new treatment hypertrophic cicatrix or the effective ways of diabetes and preparation for clinic.Being additionally provided with stearyl alcohol glycyrrhetin acid esters in pastille pressure-sensitive adhesive layer, stearyl alcohol glycyrrhetin acid esters and GLP-1 mass ratio are 1:10.Stearyl alcohol glycyrrhetin acid esters moisturizing and inflammation-diminishing function are strong, also have antibacterial, antiinflammatory, antioxidation, defying age, whitening skin lightening, effect of speckle dispelling.The medicine that pastille pressure-sensitive adhesive layer contains also includes that water soluble dietary fiber, water soluble dietary fiber are 3:7 with the mass ratio of GLP-1.The present invention is easy to treat diabetes, does not results in gastrointestinal and does not tolerates, and does not interferes with the absorption of other nutrients.The medicine that pastille pressure-sensitive adhesive layer contains also includes water soluble dietary fiber, vitamin b1, and water soluble dietary fiber, vitamin b1 and GLP-1 three's mass ratio are 2:2:6.The present invention is easy to treat diabetes, does not results in gastrointestinal and does not tolerates, and does not interferes with the absorption of other nutrients.In diabetics body, vitamin b1 level is significantly lower than normal person simultaneously, and therefore diabetics suitable vitimin supplement b1 is useful.
Medicine is provided with a surrounding layer being made up of liposome.Liposome can be monounsaturated fatty acid.The opposing to insulin can be reduced, improve administering effect.
Substrate uses water-free substrate, and substrate includes non-polar polymer and plasticizer.Moisture free substrate can improve the stability of medicine, and patch compliance is good, and adhesiveness is suitable.
Viscosifier, transdermal enhancer and the antioxidant being dispersed in substrate it is additionally provided with in pastille pressure-sensitive adhesive layer 22.Preferably to work in coordination with rush together to ooze.
First micropin includes double-decker, respectively internal layer and outer layer, and outer layer is to be made up of biodegradable polymer, and internal layer includes at least one in GLP-1, DPP-4 inhibitor both medicines, and biodegradable polymer is PLGA.
Biodegradable polymer is
Wherein ,-PEA-is-PEUR isN is the scope of 50 to 150, and m is the scope of 0.1 to 0.9；P is the scope of 0.9 to 0.1.R1 is selected from C6Alkylidene or C7Alkenylene；R2 is hydrogen or C6Alkyl；R3 is selected from hydrogen, (C2-C6) alkyl, (C2-C6) thiazolinyl and (C2-C6) alkynyl；With R4 selected from (C2-C6) alkylidene, (C2-C6) alkenylene or alkoxyl.
Permanent magnet powder granule is also distributed in pastille pressure-sensitive adhesive layer.Permanent magnet powder granule can use Ru-Fe-Mn permanent magnet powder granule.Molecular activity can be promoted by magnetic field, the activity of hydrone in human body can be promoted especially.Tourmaline powder particle is also distributed in pastille pressure-sensitive adhesive layer.
The ultimate principle of the present invention and principal character and advantages of the present invention have more than been shown and described.Skilled person will appreciate that of the industry; the present invention is not restricted to the described embodiments; the principle that the present invention is simply described described in above-described embodiment and description; without departing from the spirit and scope of the present invention; the present invention also has various changes and modifications, and these changes and improvements both fall within scope of the claimed invention.Claimed scope is defined by appending claims and equivalent thereof.
Claims (10)
- The microneedle cutaneous system of the most novel electret, including a sealing coat, it is arranged on the pastille pressure-sensitive adhesive layer inside described sealing coat, it is characterised in that, the outside of described sealing coat is provided with the electret layer that an employing electret is made, and the inner side of described pastille pressure-sensitive adhesive layer is provided with a release-controlled film layer；It is placed with described electret layer, described sealing coat, described pastille pressure-sensitive adhesive layer and described release-controlled film layer successively by outer and interior, forms a reservoir devices patch；Being provided with a microneedle array layer inside described reservoir devices patch, described microneedle array layer includes the microneedle array that a plurality of micropin is formed；A diameter of 20 microns～50 microns of described micropin, the spacing of adjacent described micropin is 1mm～1.5mm.
- The microneedle cutaneous system of novel electret the most according to claim 1, it is characterized in that, the micropin that described microneedle array is provided with includes degradable first micropin, nondegradable second micropin, and described first micropin is adjacent with described second micropin to be arranged alternately in described microneedle array layer.
- The microneedle cutaneous system of novel electret the most according to claim 1, it is characterised in that be provided with a micromotor outside described electret layer, described micromotor connects an eccentric by drive disk assembly, and described eccentric props up described electret layer.
- The microneedle cutaneous system of novel electret the most according to claim 1, it is characterised in that post a ultrasound wave genetic horizon outside described electret layer, ultrasound wave genetic horizon connects a ultrasonic output circuit；Described ultrasound wave genetic horizon includes the piezoelectric ceramic piece consistent with micropin number, and the arrangement of described piezoelectric ceramic piece is consistent with the arrangement of described micropin, and described piezoelectric ceramic piece is on same straight line with the central axis of described micropin.
- 5. according to the microneedle cutaneous system of novel electret described in claim 1 or 4, it is characterized in that, a metal electrode layer is also posted outside described electret layer, described metal electrode layer connects the polarity reversing device of an adjustment metal electrode layer polarity of electrode, described polarity reversing device connects a microprocessor system, and described microprocessor system connects a clock module.
- The microneedle cutaneous system of novel electret the most according to claim 1, it is characterised in that described pastille pressure-sensitive adhesive layer includes containing 5-fluorouracil, somatomedin, the substrate of GLP-1 or DPP-4 any one medicine of inhibitor.
- The microneedle cutaneous system of novel electret the most according to claim 6, it is characterised in that being additionally provided with stearyl alcohol glycyrrhetin acid esters in described pastille pressure-sensitive adhesive layer, stearyl alcohol glycyrrhetin acid esters and GLP-1 mass ratio are 1:10.
- 8. according to the microneedle cutaneous system of novel electret described in claim 6 or 7, it is characterised in that the medicine that described pastille pressure-sensitive adhesive layer contains also includes that water soluble dietary fiber, water soluble dietary fiber are 3:7 with the mass ratio of GLP-1.
- The microneedle cutaneous system of novel electret the most according to claim 6, it is characterised in that described medicine is provided with a surrounding layer being made up of liposome.
- The microneedle cutaneous system of novel electret the most according to claim 2, it is characterized in that, described first micropin includes double-decker, it is respectively internal layer and outer layer, described outer layer is to be made up of biodegradable polymer, and described internal layer includes at least one in 5-fluorouracil, somatomedin, GLP-1, DPP-4 inhibitor these four medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610005552.0A CN105816952A (en) | 2016-01-05 | 2016-01-05 | Novel electret microneedle transdermal drug delivery system |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610005552.0A CN105816952A (en) | 2016-01-05 | 2016-01-05 | Novel electret microneedle transdermal drug delivery system |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105816952A true CN105816952A (en) | 2016-08-03 |
Family
ID=56986899
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610005552.0A Pending CN105816952A (en) | 2016-01-05 | 2016-01-05 | Novel electret microneedle transdermal drug delivery system |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105816952A (en) |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107007927A (en) * | 2017-02-21 | 2017-08-04 | 中山大学 | A kind of microneedle array drug paste and preparation method being administered based on electric field driven |
| CN108498941A (en) * | 2018-04-25 | 2018-09-07 | 武汉德丽福生物科技有限公司 | Micropin Beauty sticking piece with and preparation method thereof |
| CN109420246A (en) * | 2017-08-31 | 2019-03-05 | 北京纳米能源与系统研究所 | The integrated microneedle patch and method of controlled drug release |
| CN109718465A (en) * | 2019-01-28 | 2019-05-07 | 深圳市中明科技股份有限公司 | 3D printing electret micropin promotees to absorb facial mask |
| CN110087723A (en) * | 2016-12-23 | 2019-08-02 | 赛诺菲 | Medicament delivery device |
| CN110151736A (en) * | 2019-07-04 | 2019-08-23 | 蚌埠医学院 | Patch and preparation method thereof |
| CN112280675A (en) * | 2020-11-03 | 2021-01-29 | 深圳市中明科技股份有限公司 | Cell culture device with electret |
| CN113577528A (en) * | 2021-08-26 | 2021-11-02 | 中国科学院深圳先进技术研究院 | Piezoelectric electret drug delivery patch for transdermal drug delivery by combining contact pressure or beating and preparation method and application thereof |
| CN113842544A (en) * | 2021-10-18 | 2021-12-28 | 中南大学 | Percutaneous permeation-promoting drug delivery device |
| CN114272511A (en) * | 2021-01-12 | 2022-04-05 | 广州新济药业科技有限公司 | Semetiluo peptide soluble microneedle patch and preparation method thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020099356A1 (en) * | 2001-01-19 | 2002-07-25 | Unger Evan C. | Transmembrane transport apparatus and method |
| CN101068591A (en) * | 2004-12-02 | 2007-11-07 | 惠普开发有限公司 | Transdermal drug delivery device |
| CN101605536A (en) * | 2006-12-22 | 2009-12-16 | 徐百 | The micro element and the method that are used for active substance transdermal delivery and sampling |
| CN202397971U (en) * | 2011-11-18 | 2012-08-29 | 中国人民解放军第二军医大学 | Electret and microneedle transdermal delivery system |
| CN104815398A (en) * | 2015-05-25 | 2015-08-05 | 成都凤磐生物科技有限公司 | Photorejuvenation system combined with microneedle sticker |
-
2016
- 2016-01-05 CN CN201610005552.0A patent/CN105816952A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020099356A1 (en) * | 2001-01-19 | 2002-07-25 | Unger Evan C. | Transmembrane transport apparatus and method |
| CN101068591A (en) * | 2004-12-02 | 2007-11-07 | 惠普开发有限公司 | Transdermal drug delivery device |
| CN101605536A (en) * | 2006-12-22 | 2009-12-16 | 徐百 | The micro element and the method that are used for active substance transdermal delivery and sampling |
| CN202397971U (en) * | 2011-11-18 | 2012-08-29 | 中国人民解放军第二军医大学 | Electret and microneedle transdermal delivery system |
| CN104815398A (en) * | 2015-05-25 | 2015-08-05 | 成都凤磐生物科技有限公司 | Photorejuvenation system combined with microneedle sticker |
Non-Patent Citations (1)
| Title |
|---|
| 陈磊 等: "微针在经皮给药系统的应用研究", 《安徽医药》 * |
Cited By (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110087723A (en) * | 2016-12-23 | 2019-08-02 | 赛诺菲 | Medicament delivery device |
| US11666739B2 (en) | 2016-12-23 | 2023-06-06 | Sanofi | Medicament delivery device |
| CN107007927A (en) * | 2017-02-21 | 2017-08-04 | 中山大学 | A kind of microneedle array drug paste and preparation method being administered based on electric field driven |
| CN109420246A (en) * | 2017-08-31 | 2019-03-05 | 北京纳米能源与系统研究所 | The integrated microneedle patch and method of controlled drug release |
| CN109420246B (en) * | 2017-08-31 | 2021-10-15 | 北京纳米能源与系统研究所 | Integrated microneedle patch and method for controlled drug release |
| CN108498941A (en) * | 2018-04-25 | 2018-09-07 | 武汉德丽福生物科技有限公司 | Micropin Beauty sticking piece with and preparation method thereof |
| CN109718465B (en) * | 2019-01-28 | 2022-01-04 | 深圳市中明科技股份有限公司 | 3D printing electret microneedle absorption-promoting mask |
| CN109718465A (en) * | 2019-01-28 | 2019-05-07 | 深圳市中明科技股份有限公司 | 3D printing electret micropin promotees to absorb facial mask |
| CN110151736A (en) * | 2019-07-04 | 2019-08-23 | 蚌埠医学院 | Patch and preparation method thereof |
| CN112280675A (en) * | 2020-11-03 | 2021-01-29 | 深圳市中明科技股份有限公司 | Cell culture device with electret |
| CN114272511A (en) * | 2021-01-12 | 2022-04-05 | 广州新济药业科技有限公司 | Semetiluo peptide soluble microneedle patch and preparation method thereof |
| WO2022152131A1 (en) * | 2021-01-12 | 2022-07-21 | 广州新济药业科技有限公司 | Semaglutide soluble microneedle patch and preparation method therefor |
| WO2023024338A1 (en) * | 2021-08-26 | 2023-03-02 | 中国科学院深圳先进技术研究院 | Piezoelectret drug delivery patch in combination with transdermal drug delivery by means of pressing or patting, and preparation method therefor and application thereof |
| CN113577528A (en) * | 2021-08-26 | 2021-11-02 | 中国科学院深圳先进技术研究院 | Piezoelectric electret drug delivery patch for transdermal drug delivery by combining contact pressure or beating and preparation method and application thereof |
| CN113842544A (en) * | 2021-10-18 | 2021-12-28 | 中南大学 | Percutaneous permeation-promoting drug delivery device |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105816952A (en) | Novel electret microneedle transdermal drug delivery system | |
| Martin et al. | Controlled-release of opioids for improved pain management | |
| Kang et al. | Microneedles for drug delivery: recent advances in materials and geometry for preclinical and clinical studies | |
| ES2310942T3 (en) | TOLTERODINE ADMINISTERED BY TRANSDERMIC AS AN ANTI-MUSCARINIC AGENT FOR THE TREATMENT OF HYPERACTIVE BLADDER. | |
| CN102657914B (en) | Micro-needle transdermal delivery patch with high penetration efficiency | |
| Shu et al. | Polyvinylpyrrolidone microneedles for localized delivery of sinomenine hydrochloride: preparation, release behavior of in vitro & in vivo, and penetration mechanism | |
| JP2008512215A (en) | Biosynchronous transdermal drug delivery | |
| TW200539907A (en) | Delivery of polymer conjugates of therapeutic peptides and proteins via coated microprojections | |
| CN202397971U (en) | Electret and microneedle transdermal delivery system | |
| US11511095B2 (en) | Portable transdermal administration patch apparatus and preparation method thereof | |
| CN103505806B (en) | electret nanoparticle transdermal drug delivery system | |
| JP2005537054A5 (en) | ||
| CN202961235U (en) | Electret sustained-release transdermal drug delivery system | |
| JP2006335754A (en) | Thin film carrying percutaneous absorption preparation and its manufacturing process | |
| CN105816442A (en) | 5-fluorouracil nanoparticle transdermal drug delivery electret preparation for treating hypertrophic scars based on action of electric field | |
| CN109481422B (en) | Graphene oxide electrothermal film transdermal patch | |
| Kumar et al. | Hydromorphone in the management of cancer-related pain: an update on routes of administration and dosage forms | |
| KR20220116085A (en) | Micro niddle patch include fucoidan | |
| Ito et al. | Usefulness of direct intratumoral administration of doxorubicin hydrochloride with an electro-osmosis–assisted pump | |
| CN1274310C (en) | Paste agent of penetrating through skin for treating arthritid and preparation method | |
| CN102205129B (en) | Novel nasal mucosa absorption enhancer | |
| CN106074460A (en) | A kind of electret and the Percutaneously administrable preparation of 5 fluorouracil associating Inhibiting proliferation cicatrix growth | |
| Krisnamurti et al. | Glucose-responsive pectin insulin patch for diabetes mellitus: A review | |
| Michaels | Therapeutic systems for controlled administration of drugs: a new application of membrane science | |
| CN206434601U (en) | A kind of new capsaicine hydrogel patch |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160803 |